Article
Oncology
Yiyi Feng, Xin Song, Renbing Jia
Summary: This study described a case in which apatinib demonstrated clinical benefit and safety in treating a patient with recurrent MCC. It highlights the potential utility of apatinib in managing MCC patients, but further clinical trials are needed to confirm its efficacy and safety.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Fangfang Gao, Jingtai Li, Haoran Liao, Pingming Fan, Minjian Wang, Yu Liu, Linwei Ding, Guankui Du
Summary: Primary squamous cell carcinoma of the breast is a rare and difficult-to-treat subtype of carcinoma. This study reports a successful case of breast squamous cell carcinoma treated with apatinib, resulting in partial remission and shrinkage of a 4 cm sublesion in the breast.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Weiwei Ke, Linlin Zhang, Xiangxuan Zhao, Zaiming Lu
Summary: The study found that the p53-m6A axis plays a crucial role in regulating the sensitivity of hepatocellular carcinoma to chemotherapy, highlighting the potential of targeting this axis in HCC therapy. By reducing METTL3 expression and increasing p53 expression, chemotherapy efficacy can be enhanced, providing a new insight into HCC treatment.
Review
Biochemistry & Molecular Biology
Katarzyna Krol, Anna Mazur, Paulina Stachyra-Strawa, Ludmila Grzybowska-Szatkowska
Summary: Lung cancer is the leading cause of death globally. Surgery is the main treatment for early stages, while combined modalities of treatment are used for advanced stages including radiochemotherapy and molecularly targeted treatment. There is a growing trend of using radiotherapy in combination with molecular therapy for locally advanced and metastatic lung cancer management, which has shown a synergistic effect and immune response modification. However, the combination of anti-angiogenic therapy and radiotherapy is not recommended due to high toxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Weihao Liu, Huan Ma, Ranxi Liang, Xijian Chen, Hongyan Li, Tu Lan, Jijun Yang, Jiali Liao, Zhi Qin, Yuanyou Yang, Ning Liu, Feize Li
Summary: Targeted radionuclide therapy based on alpha-emitters is important in cancer treatment. This study proposes a new vector for At-211 radiolabeling and demonstrates its effectiveness in inhibiting tumor growth and promoting cell apoptosis without significant toxicity to normal organs.
MOLECULAR PHARMACEUTICS
(2022)
Article
Cell Biology
Dongmei Chi, Baoqing Chen, Suping Guo, Kunhao Bai, Huali Ma, Yonghong Hu, Qiaoqiao Li, Yujia Zhu
Summary: The combination therapy of apatinib and S-1/capecitabine for ESCC patients with residual disease after dCRT demonstrated tolerable toxicity and satisfactory disease control. The study showed good efficacy and safety profile, with most common adverse events being of grade 1 to 2, and better PFS associated with the occurrence of any adverse events and better OS with the occurrence of proteinuria.
Review
Oncology
Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega
Summary: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and its pathogenesis is mainly caused by biallelic loss of the tumor suppressor gene VHL. Dysfunctional degradation of HIF due to VHL loss leads to overaccumulation of HIF, resulting in the activation of genes responsible for cell survival and proliferation in ccRCC. Previous therapies have targeted downstream effectors of HIF, but there is now a focus on interfering with upstream targets.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Weixing Jiang, Dong Wang, Xiaoqi Liu, Wei Zheng, Li Wen, Hongzhe Shi, Huijuan Zhang, Aiping Zhou, Changling Li, Jianhui Ma, Shan Zheng, Jianzhong Shou
Summary: The study evaluated the expression of PD-L1 and VEGFR-2 in smRCC patients and found that patients with PD-L1-positive and VEGFR-2-negative expression had poor prognoses. It suggests exploring alternative treatments for this subgroup of patients.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Shuguang Ju, Chen Zhou, Chongtu Yang, Chaoyang Wang, Jiacheng Liu, Yingliang Wang, Songjiang Huang, Tongqiang Li, Yang Chen, Yaowei Bai, Wei Yao, Bin Xiong
Summary: This study compared the efficacy and safety of TACE+AC and AC in the treatment of unresectable HCC. The results showed that TACE+AC significantly improved overall survival, objective response rate, and disease control rate compared to AC. The incidence of adverse events was similar between the two groups.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Tomohiro Enokida, Makoto Tahara
Summary: Anti-VEGFR therapy is crucial in treating thyroid cancer but can lead to dangerous adverse reactions. To minimize risks, physicians need to understand the characteristics of these reactions and take appropriate measures. The development of multitarget tyrosine kinase inhibitors has improved prognosis, but effective management of related adverse events is essential.
Article
Biochemistry & Molecular Biology
Yueshui Zhao, Sipeng Guo, Jian Deng, Jing Shen, Fukuan Du, Xu Wu, Yu Chen, Mingxing Li, Meijuan Chen, Xiaobing Li, Wanping Li, Li Gu, Yuhong Sun, Qinglian Wen, Jing Li, Zhangang Xiao
Summary: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, with poor prognosis. Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis and immunomodulation in NSCLC. Current research focuses on understanding the functions of VEGF in NSCLC and its interaction with the tumor microenvironment, as well as exploring novel treatment approaches targeting VEGF/VEGFR and immunotherapy.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
Article
Medicine, General & Internal
Yingchao Zhang, Xianzhao Deng, Zheng Ding, Jie Kang, Bo Wu, Bomin Guo, Youben Fan
Summary: This study reports a case of inoperable locally advanced DTC patient who underwent curative surgery after preoperative monotherapy of apatinib. The use of short-term targeted treatment with apatinib may be a promising neoadjuvant therapy for locally advanced, inoperable DTC that reduces tumor size and facilitates complete and safe lesion removal.
Review
Oncology
Valentina Schiavoni, Roberto Campagna, Valentina Pozzi, Monia Cecati, Giulio Milanese, Davide Sartini, Eleonora Salvolini, Andrea Benedetto Galosi, Monica Emanuelli
Summary: The aim of this review is to discuss novel prognostic and therapeutic markers for clear cell renal cell carcinoma (ccRCC), the most common variant of renal cell carcinoma. ccRCC is characterized by high aggressiveness, invasiveness, and metastatic potential, leading to poor prognosis and high mortality rate. This review provides an overview of the epidemiology, risk factors, established prognostic markers, and recent advances in treatment and biomarker discoveries for ccRCC.
Review
Cell Biology
Yongchang Lai, Fucai Tang, Yapeng Huang, Chengwu He, Chiheng Chen, Jiquan Zhao, Wenqi Wu, Zhaohui He
Summary: Renal cell carcinoma (RCC) is a common urinary system tumor, with clear cell renal cell carcinoma being the most prevalent subtype. Advanced RCC is treated with molecular-targeted drugs and immune checkpoint inhibitors, but resistance may occur due to the dynamic tumor microenvironment and metabolic characteristics. Novel findings on the TME and tumor metabolism in RCC may offer insights for future treatment strategies to overcome resistance.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Endocrinology & Metabolism
Wei Du, Xiangyu Shi, Qigen Fang, Xu Zhang, Shanting Liu
Summary: In the study of using apatinib to treat RAIR-DTC, patients had high objective response rate and disease control rate. The median progression-free survival and overall survival were 18 and 59 months, respectively. Adverse events were common but mostly mild to moderate.
FRONTIERS IN ENDOCRINOLOGY
(2022)
